Compare Carparts.Com Inc (PRTS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs 10X Genomics Inc — how do they compare? Carparts.Com Inc trades at $8.59 (market cap $66.42M), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 151.6× Carparts.Com Inc's market cap, and Carparts.Com Inc is more actively traded (40,287 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and 10X Genomics Inc for 92 Days on average.
| PRTS | TXG | |
|---|---|---|
Market Cap | $66.42M | $10.07B |
Volume | 40,287 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $97.74 |
52-Week Low | $3.88 | $11.48 |
Typical Hold Time | 45 Days | 92 Days |
Enterprise Value | $79.39M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $8.695, up 0.99% with a bullish technical signal. The company shows improving quarterly earnings performance, beating expectations in recent quarters, though remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, but net losses are narrowing. Analyst sentiment is positive with 60% buy ratings, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential recovery as earnings improve and losses narrow, supported by analyst optimism. Key risks include persistent negative cash flow, competitive pressures in auto parts e-commerce, and execution challenges in returning to profitability. The stock offers speculative upside if the company can sustain its earnings beat trend and stabilize revenue.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
